报告时间：2016年1月21日（星期四）上午9：00

　　报告地点：生物楼406会议室

　　报告人：刘强 教授（大连医科大学）

　　报告人简介：

　　刘强教授，美国伊利诺大学免疫学/临床医学双博士，大连医科大学副校长，肿瘤中心主任，肿瘤干细胞研究院院长，科技部中青年科技创新领军人才，科技部重大科学研究项目(973)首席科学家，教育部创新团队带头人，教育部长江学者特聘教授，国家自然基金委杰出青年基金获得者，“百千万人才工程”国家级人选，卫生部“有突出贡献中青年专家”，中国病理生理学会免疫专业委员会主任委员。美国医学及生物工程院(AIMBE)Fellow，美国中华医学基金会(CMB)杰出教授。围绕肿瘤靶向治疗的转化医学研究，刘强教授先后在J. Clin. Oncol.、Nat Commun.、Cancer Cell、PNAS、Blood、Autophagy等国际知名学术期刊发表论著近80篇。目前，已申请获批专利多项。

　　刘强教授主要从事肿瘤靶向治疗的转化医学研究，研究方向包括：1）肿瘤分子靶向治疗基础及应用；2）肿瘤干细胞信号网络与干预研究；3）肿瘤表观遗传及分化诱导治疗。

　　报告摘要：

　　The Aurora kinase family comprises three serine/threonine kinases, Aurora-A, -B, and -C, which play key roles in mitosis. Over-expression or gene amplification of Aurora kinases has been reported in a wide range of different human malignancies, and Aurora kinases have emerged as oncogenes involved in tumorigenesis. Hence, Aurora kinases represent promising targets for anti-cancer drug development. A number of Aurora kinase inhibitors (AKIs) have been discovered and are undergoing clinical trials. Recent studies have identified new functions of Aurora kinases during cancer development and have explored the mechanisms underlying the anticancer effects of AKIs. Here, we discuss the most recent advances in Aurora kinase-targeted cancer therapy, with a focus on the cancer-related roles of Aurora kinases, the signaling mediated by Aurora kinases, the cellular substrates of Aurora kinases that have been linked to tumorigenesis, preclinical and clinical AKI data, and alternative routes of Aurora kinase inhibition.

　　联系人：1809组 王璐（9620）